An analysis of the metabolic syndrome phenotype in systemic lupus erythematosus

Lupus

Volumn 20, Issue 14, 2011, Pages 1459-1465

  Parker, B ^a   Ahmad, Y ^b   Shelmerdine, J ^b   Edlin, H ^b   Yates, A P ^b   Teh, L S ^c   Bruce, I N ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL BLACKBURN HOSPITAL   (United Kingdom)

Author keywords

atherosclerosis; metabolic syndrome; systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C3; CORTICOSTEROID;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY RISK; CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIMALARIALS; CAROTID STENOSIS; CASE-CONTROL STUDIES; FEMALE; GLUCOCORTICOIDS; HUMANS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLIC SYNDROME X; MIDDLE AGED; PHENOTYPE; PREVALENCE; WAIST CIRCUMFERENCE;

EID: 82955189297     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311416695     Document Type: Article

References (33)

1. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999 ; 42: 338-346 (Pubitemid 29072852)
2. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976 ; 60: 221-225
3. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol. 1997 ; 145: 408-415 (Pubitemid 27084212)
4. Ahmad Y, Shelmerdine J, Bodill H, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): The relative contribution of classic risk factors and the lupus phenotype. Rheumatology. 2007 ; 46: 983-988 (Pubitemid 47062508)
5. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 2399-2406 (Pubitemid 37542988)
6. Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: The Toronto Risk Factor Study. Arthritis Rheum. 2003 ; 48: 3159-3167 (Pubitemid 37409327)
7. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 ; 44: 2331-2337 (Pubitemid 32977500)
8. Bruce IN. 'Not only...but also': Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology. 2005 ; 44: 1492-1502 (Pubitemid 41742464)
9. Cornier MA, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Rev. 2008 ; 29: 777-822
10. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and international association for the Study of Obesity. Circulation. 2009 ; 120: 1640-1645
11. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007 ; 49: 403-414 (Pubitemid 46135879)
12. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005 ; 28: 2289-2304 (Pubitemid 41242486)
13. Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med. 2005 ; 165: 2644-2650 (Pubitemid 41785063)
14. Grundy SM. Does the metabolic syndrome exist?. Diabetes Care. 2006 ; 29: 1689-1692 (Pubitemid 44127605)
15. Parker B, Bruce IN. The metabolic syndrome in systemic lupus erythematosus. Rheum Dis Clin North Am. 2010 ; 36: 81-97
16. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
17. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 ; 29: 288-291 (Pubitemid 34118775)
18. Gladman D, Ginzler E, Goldsmith C, et al. The development andinitial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996 ; 39: 363-369 (Pubitemid 26085211)
19. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998 ; 21: 2191-2192 (Pubitemid 28549174)
20. Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000 ; 23: 57-63 (Pubitemid 30022895)
21. Li R, Duncan BB, Metcalf PA, et al. B-mode-detected carotid artery plaque in a general population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Stroke. 1994 ; 25: 2377-2383
22. Vadacca M, Margiotta D, Rigon A, et al. Adipokines and systemic lupus erythematosus: Relationship with metabolic syndrome and cardiovascular disease risk factors. J Rheumatol. 2009 ; 36: 295-297
23. Chung CP, Avalos I, Oeser A, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: Association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007 ; 66: 208-214 (Pubitemid 46226056)
24. Sabio JM. Zamora-Pasadas M, Jimenez-Jaimez J, et al. Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus. 2008 ; 7: 849-859
25. Bellomio V, Spindler A, Lucero E, et al. Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus. 2009 ; 18: 1019-1025
26. Negron AM, Molina MJ, Mayor AM, Rodriguez VE, Vila LM. Factors associated with metabolic syndrome in patients with systemic lupus erythematosus from Puerto Rico. Lupus. 2008 ; 17: 348-354 (Pubitemid 351655804)
27. Chung CP, Oeser A, Solus JF, et al. Inflammation-associated insulin resistance: Differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008 ; 58: 2105-2112 (Pubitemid 351988102)
28. Mok CC, Poon WL, Lai JP, et al. Metabolic syndrome, endothelial injury, and subclinical atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol. 2010 ; 39: 42-49
29. Toussirot E, Gaugler B, Bouhaddi M, Nguyen NU, Saas P, Dumoulin G. Elevated adiponectin serum levels in women with systemic autoimmune diseases. Mediators Inflamm. 2010 ; 2010: 938408-938408
30. El-Magadmi M, Ahmad Y, Turkie W, et al. Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. J Rheumatol. 2006 ; 33: 50-56 (Pubitemid 43054279)
31. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998 ; 15: 539-553 (Pubitemid 28319935)
32. JAMA. 2001 ; 285: 2486-2497
33. Tso TK, Huang WN. Elevation of fasting insulin and its association with cardiovascular disease risk in women with systemic lupus erythematosus. Rheumatol Int. 2009 ; 29: 735-742